Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $146,207.31 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,667 shares of the business's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $21.93, for a total value of $146,207.31. Following the transaction, the chief operating officer now directly owns 329,977 shares of the company's stock, valued at approximately $7,236,395.61. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Anish Patel also recently made the following trade(s):

• On Tuesday, January 7th, Anish Patel sold 21,700 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.18, for a total value of $524,706.00.

Enliven Therapeutics Stock Up 1.9 %

Shares of NASDAQ ELVN traded up $0.40 during mid-day trading on Friday, hitting $21.90. 280,920 shares of the company were exchanged, compared to its average volume of 247,259. The stock has a 50 day simple moving average of $22.60 and a 200-day simple moving average of $24.13. Enliven Therapeutics, Inc. has a 1-year low of $10.90 and a 1-year high of $30.03. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -11.56 and a beta of 1.03.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ELVN. BTIG Research began coverage on Enliven Therapeutics in a report on Friday, December 13th. They issued a "buy" rating and a $42.00 price target for the company. Robert W. Baird upped their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the company an "outperform" rating in a report on Friday, November 15th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $38.25.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC increased its position in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after buying an additional 1,114 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Enliven Therapeutics in the fourth quarter valued at $97,000. ExodusPoint Capital Management LP acquired a new stake in shares of Enliven Therapeutics during the fourth quarter valued at $200,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Enliven Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company's stock valued at $232,000 after acquiring an additional 3,559 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Enliven Therapeutics during the third quarter valued at $256,000. Hedge funds and other institutional investors own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.